Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib

Dacomitinib is a second-generation, irreversible, covalent pan-HER tyrosine-kinase inhibitor (TKI). It showed potent EGFR signaling inhibition in experimental models, including first-generation TKI-resistant non-small cell lung cancer (NSCLC) cell lines. This preclinical efficacy did not translate i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zugazagoitia, Jon, Díaz, Asunción, Jimenez, Elisabeth, Nuñez, Juan Antonio, Iglesias, Lara, Ponce-Aix, Santiago, Paz-Ares, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380728/
https://www.ncbi.nlm.nih.gov/pubmed/28424775
http://dx.doi.org/10.3389/fmed.2017.00036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380728/
https://www.ncbi.nlm.nih.gov/pubmed/28424775
http://dx.doi.org/10.3389/fmed.2017.00036

Ejemplares similares